Domestic CDMO leadership Akums is India-focused with multiple manufacturing facilities and a growing CDMO footprint across oral solids, liquids, sterile injectables, hormones, and more. This presents cross-therapy CDMO partnerships opportunities for global pharma players seeking reliable Indian manufacturing scale and integrated capabilities.

API and formulation expansion Expansion into API manufacturing alongside finished-dose products broadens Akums’ value proposition for end-to-end supply to pharma companies. Sales discussions can highlight streamlined sourcing, potential cost efficiencies, and reduced supply risk for customers pursuing integrated API-to-portfolio manufacturing.

Strategic partnerships Recent and ongoing partnerships, notably with Oriflame for long-term manufacturing collaboration and asset acquisitions, indicate a readiness to scale through strategic alliances. This signals opportunities to offer co-development, contract manufacturing, and premium quality assurances to multinational brands expanding in India.

Financial health signal Solid revenue trajectory with Q1 FY27 growth in CDMO revenue contributing a large majority of total sales and a stable to rising profitability trend. This supports conversations around scalable capacity, pricing flexibility for long-term contracts, and capacity commitments to meet forecasted demand.

Growth and talent A sizable workforce and recent hires in QC and R&D indicate ongoing capability building and quality focus. This can be leveraged to position Akums as a reliable partner for complex, regulated projects requiring robust quality systems, technical expertise, and skilled personnel across development and manufacturing.